VCM
EGRX

Versant Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Versant Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7
Closed -$136 – 2087
2023
Q2 		$136 Buy
+7
New +$166 ﹤0.01% 2021
2022
Q3 		– Sell
-12
Closed -$440 – 1708
2022
Q2 		$1K Buy
+12
New +$551 ﹤0.01% 1395

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Versant Capital Management's EGRX Position: Q3 2023 in Review

Versant Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 7 shares — an estimated $136 sold.

Versant Capital Management first reported a position in EGRX in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q2 2022. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • Versant Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Versant Capital Management sold 7 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $136.
  • Versant Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2022 and held it in 2 quarters.
  • Versant Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $1K in Q2 2022.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on Versant Capital Management's 13F filing for Q3 2023, filed 12 Oct 2023.